- Increase in revenue of $166.9 million observed with FDA approved DMD drugs in Q3 of 2021; year over year increase of 37%.
- Next-generation PPMO drugs are being advanced in order to improve upon the first generation types; in addition, other mutations observed in DMD are being targeted as well.
- The pivotal EMBARK study, using SRP-9001 for the treatment of patients with DMD is expected to complete recruitment in 1st half of 2022, with results shortly after.
- Fully enhanced pipeline with 40+ clinical candidates in development provides many shots on goal.
For further details see:
Sarepta: Still A Solid Long-Term Bet On Sales And Next Generation Treatments